South Africa’s Aspen sells Australian prescription portfolio to Mylan

Share this post

Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy the South African drugmaker’s portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million).

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply